Laura Panjwani

Articles

Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC

September 8th 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

Ixazomib Benefit Sustained Across Myeloma Subgroups

September 1st 2016

Maria-Victoria Mateos, MD, PhD, provides insight on a subanalysis of the TOURMALINE-MM1 trial, the impact of ixazomib's (Ninlaro's) approval, and the future of triplet combinations in the treatment multiple myeloma.

Multiple Subgroups Needed to Properly Treat Patients With GEJ Cancers

August 30th 2016

Richard J. Bold, MD, discusses the reasoning to break gastroesophageal junction cancers into multiple subgroups and why it is important for treatment and surgical decisions.

NEJM Data Highlights Daratumumab Benefit in Refractory Multiple Myeloma

August 27th 2016

Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.

Early Potential Seen With Immunotherapy in Glioblastoma, But Questions Remain

August 26th 2016

David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.

Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma

August 25th 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Expert Says Nivolumab Poised to Change Standard of Care in SCCHN

August 23rd 2016

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment

August 21st 2016

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Lead Investigator Emphasizes Impact of Equivalent Efficacy With Trastuzumab Biosimilar in HER2+ Breast Cancer

August 19th 2016

Hope S. Rugo, MD, discusses the recent findings with MYL-1401O and the role of biosimilars in patients with HER2-positive breast cancer.

Expert Recaps Recent Developments in HER2+ Breast Cancer

August 17th 2016

Chau T. Dang, MD, discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

Collaborative Effort Fuels Sarcoma Advancements

August 15th 2016

Denise Reinke, MS, NP, discusses the Sarcoma Alliance for Research through Collaboration, as well as the challenges and up-and-coming advancements in sarcoma.

Investigator Highlights Remarkable Responses With Pembrolizumab in Sarcoma

August 12th 2016

Treatment with pembrolizumab (Keytruda) led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Immunotherapy Transforms Melanoma Care, But Challenges Remain

August 12th 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Weber Discusses Sequential Versus Concurrent Immunotherapy in Melanoma

August 9th 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Caring for US Veterans Helped Lead Iraqi Immigrant to Develop Prostate Cancer Advances

August 6th 2016

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

ROS1, TRK Intriguing Targets for NSCLC

August 6th 2016

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non–small cell lung cancer, although they are not commonly considered while doing mutation testing.

New Checkpoint Target Emerges in Bladder Cancer

August 4th 2016

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Researcher Discusses Role for Maintenance Olaparib in Ovarian Cancer

August 3rd 2016

Charlie Gourley, PhD, MBChB, discusses the potential use of olaparib (Lynparza) as a maintenance therapy for patients with ovarian cancer.

ASCT Retains Key Role in Myeloma Care

August 3rd 2016

Andrzej Jakubowiak, MD, discusses the impact of a recent cross-study comparison analysis and the continued role of autologous stem cell transplantation in treatment of patients with multiple myeloma.

Immunotherapy, Targeted Options Emerge in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, provides insight on the potential of glembatumumab vedotin (CDX-011) and immunotherapies on the horizon in the field of triple-negative breast cancer.